Drug Trial Radar · NCT04484025
SPI-1005 Treatment in Moderate COVID-19 Patients
Last checked: Nov 19, 2026Latest source record: Oct 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 12, 2021
Primary completion
Dec 31, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Sound Pharmaceuticals, IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.
Conditions
- Covid19
- Corona Virus Infection
- Coronavirus
- Coronavirus Infection
Interventions
EbselenDrug
Glutathione peroxidase mimetic
PlaceboDrug
Matching placebo containing excipients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse eventsTime frame: 30 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Yale University
New Haven, Connecticut
St. Luke's Cystic Fibrosis Center of Idaho
Boise, Idaho
Kansas University Medical Center
Kansas City, Kansas
Washington University in St. Louis
St Louis, Missouri
Duke University
Durham, North Carolina
Wake Forest University
Winston-Salem, North Carolina
University of Texas Southwestern
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.